P53 protein variants and therapeutic uses thereof

Details P53 protein variants and therapeutic uses thereof P53 protein variants and therapeutic uses thereof

2005-08-23

2005-08-23

Ungar, Susan (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S320100

Reexamination Certificate

active

06933373

ABSTRACT:
Proteins derived from the product of tumor suppressor gene p53 and having enhanced functions for therapeutical use are disclosed. The proteins advantageously have enhanced tumour suppressor and programmed cell death inducer functions, particularly in proliferative disease contexts where wild-type p53 protein is inactivated. Nucleic acids coding for such molecules, vectors containing same, and therapeutical use thereof, particularly in gene therapy, are also disclosed.

REFERENCES:
patent: 5573925 (1996-11-01), Halazonetis
patent: WO 94/12202 (1994-06-01), None
patent: WO 95/09916 (1995-04-01), None
patent: WO 95/16771 (1995-06-01), None
patent: WO 95/17213 (1995-06-01), None
patent: WO 96/16989 (1996-06-01), None
Bowiet et al (Science, 1990, 257:1306-1310).
Burgess et al (J. Cell Bio., 1990, 111:2129-2138).
Lazar et al (Mol. Cell. Biol., 1988, 8:1247-1252).
Orkin et al(REport and Recommendatson of the Panel to Assess the NIH investment in Research on GEne Therapy, 1995).
Marshall (Science, 1995, 269:1050-1055).
Culver et al (TTIG, 1994, 1:174-1780).
Sun et al (J. Clin. Invest., 1995, 96:1535-1547).
Hodgson (Exp. Opin. THer. Patents, 1995, 5:459-468).
Miller et al (FASEB J., 1995, 9:190-199).
Nature Biotechnology, 19976, 15:815).
Gura (Science 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Reed et al. “p53 domains: suppression, transformation, and transactivation”Gene Expression3(1):95-107 (1993).
Pietenpol et al. “Sequence-specific transcriptional activation is essential for growth suppression by p53”Proc. Natl. Acad. Sci. USA91:1998-2002 (1994).
Brown et al. “The Tumor Suppressor p53 and the Oncoprotein Simian Virus 40 T Antigen Bind to Overlapping Domains on the MDM2 Protein”Molecular&Cellular Biology13(11):6849-6857 (1993).
Wu et al. “Alternatively Spliced Forms in the Carboxy-Terminal Domain of the p53 Protein Regulate Its Ability to Promote Annealing of Complementary Single Strands of Nucleic Acids”Molecular&Cellular Biology15(1): 497-504 (1995).
Attardi et al. “Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis”The EMBO Journal15(14): 3693-3701 (1996).
Hu et al. “Sequence Requirements for Coiled-Coils: Analysis with λ Repressor-GCN4 Leucine Zipper Fusions”Science250: 1400-1403 (1990).

Affiliated with

Also associated with

Rating

P53 protein variants and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P53 protein variants and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P53 protein variants and therapeutic uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3476118